19. Use of the vector as defined in claim 15, or the chimeric peptide construct as defined in any of claims 7 to 13, in association with a pharmaceutically acceptable carrier in the preparation of a pharmaceutical composition for use in treating a hyperproliferative disease, wherein said hyperproliferative disease is preferably:

- (i) a non-cancerous hyperproliferative disorder selected from the group consisting of psoriasis, benign prostatic hypertrophy, rheumatoid arthritis, inflammatory bowel disease, osteoarthritis, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, vascular occlusion, restenosis, atherosclerosis, and oral hairy leukoplakia, and/or

- (ii) a cancer selected from the group consisting of acute myelogenous leukaemia, chronic lymphocytic leukaemia, multiple myeloma, Hodgkin's disease, non-Hodkin's lymphoma, B cell, cutaneous T cell lymphoma, and brain, lung, breast, ovarian, head and neck, bladder, gastric, pancreatic, head, neck, renal, prostate, colorectal, oesophageal, and thyroid cancer, uveal melanoma and melanoma;

wherein the hyperproliferative disease is preferably a tumor, preferably a cancer tumor in a human patient, still preferably a lymphoma, even more preferably a chronic lymphocytic leukemia (CLL).

or a parasitic disease, wherein said parasitic disease is preferably due to an infection with a parasite selected from Trypanosoma, Theileria or Plasmodium.